Kuwata T, Kitagawa M, Takemura T, Hirokawa K
Department of Pathology, Faculty of Medicine, Tokyo Medical and Dental University, Japan.
Gen Diagn Pathol. 1995 Oct;141(2):131-9.
Proliferative activity (PA) and p53 over-expression were assessed in 68 cases of primary ovarian epithelial tumors of variable grades of malignancy by immunohistochemical methods using antibodies to PCNA (proliferative cell nuclear antigen) and p53 molecule. First, we compared the values in benign tumors, tumors of borderline malignancy and malignant tumors. Malignant tumors possessed higher PA value (26.8 +/- 14.7%) than benign tumors (1.6 +/- 1.4%), and tumors of borderline malignancy exhibited an intermediate value (11.4 +/- 5.1%). Intranuclear accumulations of p53 product were more frequently observed in malignant tumors (16/32, 50%) than in tumors of borderline malignancy (3/9, 33%). None of the benign tumors exhibited p53 over-expression. In malignant tumors, PA correlated well with the histologic grade of tumors, although the histologic type and stage of the diseases did not correlate significantly with PA. Then, we focussed on the cases of malignant ovarian cancer composed of heterogeneous lesions showing a different grade of malignancy; invasive lesion (IL), non-invasive lesion (NIL), and benign appearing lesion (BAL). PA of NIL was almost identical with that of IL (19.6 +/- 13.5% vs. 23.3 +/- 12.6%), while BAL showed significantly lower PA (2.1 +/- 3.0%, p < 0.001) than the above two lesions and was similar to that of benign tumors. Furthermore, p53 over-expression was never observed in BAL, even in cases in which IL and/or NIL showed p53 over-expression. Thus, the results indicated that histologically benign-appearing lesions of malignant ovarian epithelial tumors possessed a biologic character similar to benign tumors. Collectively, all these findings would support the concept that a part of malignant ovarian epithelial tumors would be derived from benign tumors through progressive transformation.
采用抗增殖细胞核抗原（PCNA）和p53分子的抗体，通过免疫组化方法对68例不同恶性程度的原发性卵巢上皮性肿瘤的增殖活性（PA）和p53过表达进行评估。首先，我们比较了良性肿瘤、交界性恶性肿瘤和恶性肿瘤中的这些数值。恶性肿瘤的PA值（26.8±14.7%）高于良性肿瘤（1.6±1.4%），交界性恶性肿瘤的值介于两者之间（11.4±5.1%）。p53产物的核内积聚在恶性肿瘤中（16/32，50%）比交界性恶性肿瘤中（3/9，33%）更常见。良性肿瘤均未表现出p53过表达。在恶性肿瘤中，PA与肿瘤的组织学分级密切相关，尽管疾病的组织学类型和分期与PA无显著相关性。然后，我们关注由不同恶性程度的异质性病变组成的恶性卵巢癌病例；浸润性病变（IL）、非浸润性病变（NIL）和外观良性病变（BAL）。NIL的PA与IL几乎相同（19.6±13.5%对23.3±12.6%），而BAL的PA显著低于上述两种病变（2.1±3.0%，p<0.001），与良性肿瘤相似。此外，即使IL和/或NIL表现出p53过表达，BAL中也从未观察到p53过表达。因此，结果表明，恶性卵巢上皮性肿瘤中组织学上外观良性的病变具有与良性肿瘤相似的生物学特征。总体而言，所有这些发现都支持这样一种观点，即一部分恶性卵巢上皮性肿瘤可能通过渐进性转化从良性肿瘤衍生而来。
